By auenleben. CC0 Creative Commons.

Mexicans had a scare this week when it was revealed that national company Hova Health had made public the personal and clinical information of millions of clients. Later on, COFEPRIS warned Mexicans of the dangers of buying medicines online.

In international news, New York becomes the latest US state to sue Purdue Pharma for the latter’s role in the opioid crisis. Pfizer and Novo Nordisk invest in research and scientists claim to have regenerated eye cells in blind mice, allowing them to see light.

Mexico Health Review spoke with Germán Fajardo, Dean of UNAM’s School of Medicine,  on the job prospects of Mexican doctors.

Now, jump in last week’s highlights:

 

National

Mexican tech company Hova Health exposes 2.3 million clinical files and personal information, including names, addresses and dates of birth. The company had a contract for equipment and services with Michoacan’s government.

The Business Coordination Council (CCE) plans to present President-Elect López Obrador with three priorities to strengthen the Mexican healthcare sector.

COFEPRIS warns that between 50 and 90 percent of medicines sold online might be compromised.

 

International

New York sues Purdue Pharma for its role in the US opioid crisis. The state accuses the pharmaceutical of widespread fraud in the marketing of opioids including downplaying the addiction risk of these medications.

Pfizer goes back to neurodegenerative research by backing Magnolia Neurosciences, which will focus on early-life neurological processes. Pfizer also backed German BioNTech to the tune of US$425 million for the development of biotechnological flu vaccine.

Novo Nordisk acquires Bristol Diabetes spin-out Ziylo for US$800 million. This is just Novo Nordisk’s latest effort to create a “smart insulin” that can turn on only when glucose levels rise and thus prevent the risk of hypoglycemia.

Scientist claim to activate cells in the eyes of blind mice, allowing them to see light. They expect this achievement to be step forward for the development of treatments for genetic eye diseases.

Tagged with →  
Share →

Leave a Reply

Your email address will not be published. Required fields are marked *